阿托伐他汀钙序贯治疗延缓冠状动脉病变进展的临床研究

Sequential Treatment with Atorvastatin Calcium Delays Progression of Coronary Artery Disease

目的给予经皮冠状动脉介入治疗术(percutaneous coronary interventions,PCI)患者阿托伐他汀钙序贯治疗,通过冠状动脉定量分析(quantitative coronary angiography,QCA)评价冠状动脉病变进展情况。方法选择行PCI治疗患者56例,用电脑数字随机法分为观察组和对照组,每组28例。观察组给予PCI术后常规用药+阿托伐他汀钙序贯治疗(阿托伐他汀钙40mg每晚顿服,3个月,继之长期应用阿托伐他汀钙20mg每晚顿服),对照组给予PCI术后常规用药+辛伐他汀治疗(辛伐他汀20mg每晚顿服)。所有患者均在PCI术后6～9个月复查冠状动脉造影,通过QCA评价冠状动脉病变情况。结果对照组冠状动脉病变较观察组有明显进展,2组冠状动脉病变进展分类比较差异有统计学意义(P<0.05)。结论 PCI术后给予阿托伐他汀钙序贯治疗可以延缓冠状动脉病变进展。

Objective To evaluate the effect of sequential treatment with atorvastatin calcium on the progression of coronary artery disease using quantitative coronary angiography （QCA） in patients who underwent percutaneous coronary interventions （PCI）. Methods Fifty-six patients who underwent PCI were randomly divided into observation group and control group,with 28 pa- tients in each group. The observation group was given conventional medication and sequential treatment with atorvastatin calcium （atorvastatin calcium 40 mg every night for 3 months, and then 20 mg every night）. The control group only received simvastatin 20 mg every night. Coronary angiography was performed again 6-9 months after PCI and coronary artery lesions were evaluated by QCA. Results Coronary artery lesions significantly progressed in control group, compared with observation group （P can delay the progression of 0. 05）. Conclusion Sequential treatment with atorvastatin calcium coronary artery disease after PCI.